NCT02104388 - Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

August 4, 2015

Study Completion Date

August 4, 2015

Conditions

Corneal Epithelial Disorders

Interventions

DRUG

SJP-0035 Ophthalmic Solution

DRUG

Vehicle of SJP-0035 Ophthalmic Solution

Trial Locations (17)

14642

Senju Investiational Site, Rochester

23502

Senju Investigational Site, Norfolk

27262

Senju Investigational Site, High Point

41017

Senju Investigational site, Edgewood

57701

Senju Investigational Site, Rapid City

60169

Senju Investigational Site, Hoffman Estates

64111

Senju Investigational Site, Kansas City

72205

Senju Investigational Site, Little Rock

91107

Senju Investigational Site, Pasadena

91206

Senju Investigational Site, Glendale

91741

Senju Investigational Site, Glendora

92647

Senju Investigational Site, Huntington Beach

92663

Senju Investigational Site, Newport Beach

93454

Senju Investigational Site, Santa Maria

93534

Senju Investigational Site, Lancaster

94954

Senju Investigational Site, Petaluma

07650

Senju Investigational Site, Palisades Park

All Listed Sponsors

lead

Senju Pharmaceutical Co., Ltd.

INDUSTRY